[Recording: you must advance to minute 2:45 where the presentation starts]
The presentation reviews terms and analytic methods used in the economic evaluation of healthcare interventions, how US public and private payers consider information on cost and effectiveness in making value-based coverage and reimbursement decisions, and implications for the adoption in clinical practice of new genomic technologies.
Scott Grosse is a senior health economist employed in the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, where he has worked since 1996. He has degrees in economics and public health from the University of Michigan. He conducts health services research on rare disorders and neurodevelopmental disorders and public health strategies, such as folic acid fortification and newborn screening. He has over 200 peer-reviewed publications, including widely cited papers on economic evaluation methods and the clinical utility of genomic technologies. Recent publications include an article in Health Affairs that used health insurance claims data to quantify the real-world impact of a precision medicine—ivacaftor—on hospitalizations for patients with eligible CFTR genotypes.
Shreya Malhotra is an oncology genetic specialist at Ambry Genetics for the coastal region of the USA. She received her MS in Genetic Counseling from Sarah Lawrence College. In her current role, she serves as a clinical liaison for the field team to educate health care providers and other key opinion leaders on genetic testing and genomic medicine. Prior to her role at Ambry, Shreya served as the genetic counselor and clinic/ research coordinator for the PTEN clinic at Cleveland Clinic. Shreya received her BS in Economics from New York University. She is passionate about cancer genetics, business development and clinical research.
Subscribe to receive notifications for future webinars.
Subscribe